Mitsubishi UFJ Asset Management
VERV

Mitsubishi UFJ Asset Management’s Verve Therapeutics VERV Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,824
Closed -$251K – 1645
2025
Q1 		$251K Buy
54,824
+4,594
+9% +$30.8K ﹤0.01% 934
2024
Q4 		$313K Buy
50,230
+2,742
+6% +$15.5K ﹤0.01% 926
2024
Q3 		$230K Sell
47,488
-4,483
-9% -$26K ﹤0.01% 946
2024
Q2 		$254K Buy
51,971
+32,958
+173% +$207K ﹤0.01% 933
2024
Q1 		$252K Sell
19,013
-871
-4% -$11.6K ﹤0.01% 934
2023
Q4 		$258K Buy
19,884
+3,405
+21% +$42.2K ﹤0.01% 985
2023
Q3 		$219K Buy
16,479
+871
+6% +$14K ﹤0.01% 1013
2023
Q2 		$293K Buy
+15,608
New +$260K ﹤0.01% 989

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mitsubishi UFJ Asset Management's VERV Position: Q2 2025 in Review

Mitsubishi UFJ Asset Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 54,824 shares — an estimated $251K sold.

Mitsubishi UFJ Asset Management first reported a position in VERV in Q2 2023 and held it in 8 quarters. The position peaked at $313K in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Mitsubishi UFJ Asset Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 54,824 Verve Therapeutics shares in Q2 2025, an estimated $251K.
  • Mitsubishi UFJ Asset Management first reported a position in Verve Therapeutics in Q2 2023 and held it in 8 quarters.
  • Mitsubishi UFJ Asset Management's Verve Therapeutics position peaked at $313K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.